powering
next generation
precision medicines

Jessica brings a wealth of experience to her role, having served as corporate counsel for companies within 5AM Ventures’ 4:59 Initiative. Prior to that, she was responsible for overseeing corporate contracts and negotiated several major licensing and strategic transactions during her two-year tenure as associate corporate counsel at Editas Medicine. Preceding her time at Editas, she was an associate in the Life Sciences and IP Transactions groups at Ropes & Gray, LLP. While at Ropes & Gray, she specialized in licensing transactions, SEC compliance and public fundraising for life sciences companies. She earned her J.D. from Boston College and also holds a B.A. in Philosophy and a B.S. in Psychology from Boston College.

Carl is a renowned professional in the field of translational medicine and diagnostics with over 17 years of experience in drug development and technology advancement. In his previous role as the Vice President and Head of Oncology Translational Medicine at AstraZeneca Pharmaceuticals, he led a global team, spearheading biomarker strategy and translational sciences to support oncology drug development. Carl’s career also includes leadership positions at Novartis Institutes for BioMedical Research and the National Cancer Institute. He has made significant contributions to the field, with over 600 publications to his name and a reputation for mentoring future leaders in the pharmaceutical and biomedical sectors. Driven by a passion for lifelong learning and effective communication, he continues to shape the landscape of healthcare innovation. He holds a Ph.D. in Biophysical Chemistry from The Johns Hopkins University and a B.S. in Chemistry from the College of William and Mary.

Kristian is a seasoned technologist renowned for his expertise in cloud-native software engineering and computational biology. Over the course of his career, he’s made significant contributions to genomics, including the development of groundbreaking methods like MuTect and platforms such as GATK and Terra. His leadership roles at the Broad Institute have seen him drive innovation, including a 1M participant whole genome variant storage solution on Google BigQuery and the launch of EUA COVID-19 diagnostic infrastructure delivering > 100,000 results per day. Kristian’s extensive experience and commitment to advancing human health through technology make him a distinguished figure in the field. He holds a B.S. in Computer Science from Cornell University.

Travis is a seasoned scientist and developer with a track record of taking novel genomic technologies from conception through to clinical product launch. Travis has held key assay development roles at Ion Torrent Systems, Vanderbilt University Medical Center, Foundation Medicine, Thrive Earlier detection, and Exact Sciences. At Foundation Medicine, Travis had a key leadership role in the development and launch of their flagship circulating tumor DNA assay, taking it through different stages of commercialization and ultimately through FDA approval. At Thrive Earlier Detection, Travis focused on the development of CancerSEEK, a blood-based diagnostic test for early cancer detection and a program that was acquired by Exact Sciences. Travis completed his PhD at the University of Toronto.

Kristy Cobill is Head of People at Precede Biosciences, where she leads people strategy, talent development, and organizational design to support the company’s growth and evolving operating model. She is responsible for building scalable People infrastructure, strengthening performance management, and fostering a high-performing, inclusive culture aligned with business priorities.

Kristy brings broad experience across biotech, technology, and nonprofit organizations. Most recently, she served as a senior HR partner and consultant, advising companies on performance frameworks, compensation strategy, and employee lifecycle design. Prior to this, she held progressive HR leadership roles at Syros Pharmaceuticals, where she partnered with executive leadership on organizational transformation, scaled the company through rapid growth, and supported commercial launch planning.

Kristy holds a BA in Communication from Western New England University and is an Insights Discovery Practitioner.

Matt brings 15 years of experience in computational biology and epigenomics to Precede, and is a leader at the forefront of this dynamic field. With a Ph.D. from Duke University and a postdoc from MIT, his expertise lies in applying computational and statistical techniques to unravel the complex relationships between genetics, epigenetics, chromatin, and gene expression in human disease. For almost a decade, Matt led computational biology at Syros Pharmaceuticals, a company focused on discovering novel therapeutic targets using an advanced analysis of the disease epigenome, leading to multiple ongoing clinical trials. At MIT, Matt worked in the Kellis lab jointly between MIT computer science and the Broad Institute, where he contributed to groundbreaking epigenomic discoveries such as the characterization of chromatin state of the diversity of cell types in the human body through the NIH Epigenome Roadmap Project.

Dan is Precede Bio’s clinical laboratory director and holds the credentials of High-complexity Clinical Laboratory Director (HCLD) and Clinical Consultant (CC) from the American Board of Bioanalysis (ABB) and a Certificate of Qualification in Molecular Genetics from the NY State Department of Health. Dan, as Section Head of Molecular Pathology and Medical Director of Molecular Genetics at Cleveland Clinic, revitalized the service from 2016-2022. Dan established molecular pathology services at other medical institutions: Saint Barnabas Medical Center, William Beaumont Hospital (now Corewell Health), and Houston Methodist Hospital. He has served on the faculty at Lerner College of Medicine, Michigan State University, Downstate Medical Center, Baylor College of Medicine, Weill Cornell Medical College, and Beaumont’s School of Medical Technology. He has been an officer and clinical laboratory director at several biotech start-up companies/reference laboratories.

Dan is well-published in molecular diagnostics and has lectured widely. He served on multiple College of American Pathologists committees, including most recently, the Molecular Oncology Committee. He was a member and consultant to the Clinical and Molecular Genetics Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, US FDA through 2022.

Dan served on the Board of Directors for the American Association for Clinical Chemistry, ABB, and the Association for Molecular Pathology, of which he has been President.

Jen is an accomplished healthcare operator, having worked across all aspects of biotech, from leading discovery research to driving commercial product launches. Most recently, Jen served as Chief Operating Officer for a stealth Flagship Series A company and as Operations Lead within her broader origination team. In her role as COO, she was responsible for successfully growing the team, setting strategic direction, leading both R&D and operations, and driving financing activities. In her capacity as Operations lead, she supported the initiation of 6 seed stage companies and was responsible for driving key facets of operational excellence across this portfolio of early-stage companies. Prior to joining Flagship, Jen was the VP of Commercial & Launch Operations for North American EMD Serono, a role that included leading delivery of four new product launches in two years, including targeted oncology medicine in lung cancer launched with a CDx. Prior to this, Jen advised healthcare clients across R&D and commercial for over eight years as a consultant at the Boston Consulting Group. Jen is passionate about diversity in science and has taken a lead role in defining and driving diversity efforts in each of her prior roles. Jen received her PhD in Biological Chemistry from MIT.

Humphrey has more than 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions. He has served as Chief Medical Officer at several emerging biotechnology companies, including Harbour BioMed, Stingthera and Silicon Therapeutics; CMO in Residence at Roivant Sciences; and Chief of Medical Oncology at Evelo Biosciences, a Flagship Pioneering company. Prior to this, Humphrey held senior roles at AstraZeneca as Clinical Vice President Translational Medicine, Oncology; Novartis as Executive Director, Oncology Translational Laboratories; and Biogen. Previously, in academia, he was Assistant Professor at The Scripps Research Institute, Research Fellow at the Whitehead Institute at MIT and Clinical Fellow at Harvard Medical School, and he completed his internship at the Memorial University of Newfoundland. He is a Fellow of the College of American Pathologists and has authored nearly 100 publications. He holds a bachelor’s degree in Biochemistry and medical degree from the University of Cambridge, as well as an MS in Bioinformatics from Brandeis.

Josephine brings more than a decade of corporate and business development experience supporting the development and commercialization of cancer diagnostics and genomic innovator products. Previously, Josephine was Vice President of Business Development at Exact Sciences following the acquisition of Thrive Earlier Detection, a healthcare company focused on developing a blood-based multi-cancer early detection test.

Prior to Thrive, she led Business Development at 10x Genomics where she oversaw all business development activities, and implemented strategic partnerships to accelerate and strengthen 10x Genomics’ platform and application pipeline. Josephine additionally executed numerous partnerships as part of the Biopharma business development team at Foundation Medicine. She started her scientific career at the Genomics Institute of the Novartis Research Foundation and the Scripps Research Institute developing advanced genomic technologies.

Josephine completed her PhD in Molecular Biology at UCLA and received her MBA with a focus on Health Care Management & Finance from the Wharton School.

Geoff is committed to advancing precision medicine through the development of high-quality and accessible CLIA-certified and FDA-approved diagnostic products across tissue and liquid biopsies. Geoff serves as Chief Product Development Officer at Precede Biosciences, where he leads a team of awesome developers. Together, he and the team have worked to develop and operationalize Precede’s proprietary wet lab platform that profiles the transcriptional biology underlying cancer and other diseases from a simple blood test. Geoff has extensive experience developing NGS-based molecular diagnostic products having played leading roles at PacBio, Foundation Medicine, Thrive Earlier detection, and Exact Sciences. Geoff completed his Ph.D at Stanford University.

Rajesh Ramaswamy is Head of AI at Precede Biosciences, where he leads strategy, development and deployment of AI and data systems for diagnostic and exploratory products. He is responsible for establishing AI capabilities to enable high-performing diagnostic tests at speed and quality, as well as advancing AI agents to enhance efficiency.

Rajesh brings deep experience in AI with impact across quantitative finance, life sciences, and biopharma. Most recently, he served as SVP, Head of AI at SAIL Biomedicines, where he built its AI platform for RNA medicines, including the in vivo CAR-T program. Previously, he established machine learning and data science capabilities at EMD Serono, contributing to development and commercialization of multiple therapies, including a leading treatment for relapsing multiple sclerosis.

He holds a PhD in Computer Science from ETH Zurich and was an Alexander von Humboldt Fellow, with training in applied mathematics, engineering, and computing.

Christine brings over 25 years of experience spanning diagnostic development, regulatory strategy, and clinical laboratory operations. As Chief Development Officer at Precede Biosciences, she leads advancement of the company’s diagnostic portfolio from early development through regulatory approval and launch readiness. Prior to joining Precede, she most recently led Precision Medicine diagnostic strategy for GU/GYN cancers at AstraZeneca.

Previously, Christine served as Deputy Office Director for Personalized Medicine, OHT7, at the FDA’s Center for Devices and Radiological Health (CDRH), where she led the Personalized Medicine team and Division of Molecular Genetics and Pathology. Before joining FDA, she was Senior Vice President of Product Development at Foundation Medicine, where she played a pivotal role in building the CDx development program leading to many “industry firsts” with FDA approval of multiple breakthrough products.

Dr. Vietz holds a PhD in Biomedical Engineering and a BS in Chemical Engineering from the University of Rochester.